LiverMultiscan MRI device receives FDA clearance, launches at annual meeting

SAN FRANCISCO — The LiverMultiscan, an MRI device poised to detect early liver disease, officially received their FDA clearance and launched in the United States at The Liver Meeting 2015.

The device, manufactured by Perspectum Diagnostics, has been used since 2014 for research purposes, takes 15 minutes to complete the scan and is the “only imaging test cleared to detect early-stage liver disease,” according to the press release.

“LiverMultiScan is a novel non-invasive imaging technology with the potential to dramatically change the way we approach diagnosis of liver diseases such as NAFLD. Recent published data suggest that this modality can rapidly differentiate normal liver from fibrotic NASH and then accurately predict outcomes based on the liver, inflammation, fibrosis (LIF) score,” Col. Stephen A. Harrison, MD, FACP, FAASLD, said in the press release. “Further studies are warranted to confirm these findings, but we are excited about the possibilities this imaging modality offers for the future in NASH diagnostics.”

The manufacturer recently announced the receipt of $5 million in financing, including investment from the University of Oxford and Oxford University Hospitals NHS Trust, according to the abstract.

“This has been a very important year for Perspectum. We have expanded our global footprint with installations of LiverMultiScan in many new treatment and research centers around the world and we continue to make great progress in our strategy for global expansion,” Rajarshi Banerjee, CEO of Perspectum Diagnostics said in the release. “Our successful financing and FDA clearance represent strong validation of our technology, and we continue to be very pleased that leading investors recognize the potential of our business model to improve patient care and play an essential role in clinical research to develop new therapies to treat liver disease.”